PASO to conduct Odonate study of new anti-cancer drug
Peninsula & Southeast Haematology and Oncology Research Group have commenced the Odonate Therapeutics Inc research study of the new anti-cancer drug, tesetaxel, as a possible treatment for human epidermal growth factor receptor 2 (HER2) negative, hormone receptor (HR) positive breast cancer that is locally advanced or spread to one or more body parts.
The key focus of this particular study is to investigate the efficacy and functionality of how well the combination of tesetaxel and reduced dose of capecitabine perform together.
Secondary purposes of the study are to determine any side-effects that participants might demonstrate throughout the trial in regards to nominated treatments and medications.
The combination, if proven effective, would allow many patients to avoid hospital based therapies.
This study will be carried out in approximately 180 centres/sites in 20 countries, including at PASO’s centre which is based in Frankston Private Hospital, making this study accessible to those based in the City of Frankston, Mornington Peninsula and surrounding areas.
Approximately, 600 participants who have been diagnosed with breast cancer that is locally advanced or has spread to one or more body parts, and who have been treated previously with a taxane are invited to participate in this study.
If you would like to find out more about the CONTESSA trial, please follow this link.
Alternatively, you can speak to PASO’s clinical trials team:
Phone: (03) 9771 8907 | Email: email@example.com